S R Merger1, W Kerner2, M Stadler3, A Zeyfang4, P Jehle5, M Müller-Korbsch6, R W Holl7. 1. Division of Endocrinology, Department of Internal Medicine, Ulm University, Germany. Electronic address: sigrun.merger@online.de. 2. Klinikum Karlsburg, Department of Diabetes, Germany. 3. King's College London, Diabetes Research Group, Denmark Hill Campus, 10, Cutcombe Road, SE5 9RS London, UK; Hietzing Hospital Vienna, 3rd Medical Department, Wolkersbergenstr. 1, 1130 Vienna, Austria. 4. Bethesda Hospital Stuttgart, Hohenheimer Strasse 21, 70184 Stuttgart, Germany. 5. Evangelisches Krankenhaus, Wittenberg, Department of Internal Medicine, Germany. 6. Wilhelminenspital Wien, Department of Internal Medicine, Austria. 7. University of Ulm, Institute of Epidemiology and Medical Biometry, ZIBMT, Ulm, Germany; German Center for Diabetes Research (DZD), Germany.
Abstract
BACKGROUND: A growing number of people with type 1 diabetes (T1DM) are identified with features of metabolic syndrome (MS) known as "double diabetes", but epidemiologic data on the prevalence of MS in T1DM and its comorbidities are still lacking. Aim of this cross sectional study is to better estimate the prevalence of MS in T1DM, and to assess its association with comorbidities. METHODS: Data of 31,119 persons with autoimmune diabetes mellitus were analysed for signs of MS and presence of late complications. Double diabetes was defined as T1DM coexisting with MS (obesity, hypertension, dyslipidemia). Multiple linear or logistic regression analyses were performed to identify associations between double diabetes and late complications. RESULTS: 25.5% (n=7926) of persons with T1DM presented additionally the MS. Persons with double diabetes showed significantly more macrovascular comorbidities (coronary heart disease 8.0% versus 3.0% w/o MS, stroke 3.6% versus 1.6%, diabetic foot syndrome 5.5% versus 2.1%). Also microvascular diseases were increased in people with double diabetes (retinopathy 32.4% versus 21.7%, nephropathy 28.3% versus 17.8%). Both macrovascular and microvascular comorbidities were increased independent of glucose control, even if patients with good metabolic control (HbA1c <7.0%, 53mmol/mol) showed significantly less macrovascular (coronary heart disease 2.3% versus 1.8%, p<0.0001) and microvascular problems (retinopathy 8.7% versus 6.6%, p<0.0001). CONCLUSIONS: Double diabetes seems to be an independent and important risk factor for persons with T1DM in developing macrovascular and microvascular comorbidities. Therefore, patients should be identified and development of MS should be avoided. Longterm studies are needed to observe the effect of insulin resistance on patients with autoimmune diabetes.
BACKGROUND: A growing number of people with type 1 diabetes (T1DM) are identified with features of metabolic syndrome (MS) known as "double diabetes", but epidemiologic data on the prevalence of MS in T1DM and its comorbidities are still lacking. Aim of this cross sectional study is to better estimate the prevalence of MS in T1DM, and to assess its association with comorbidities. METHODS: Data of 31,119 persons with autoimmune diabetes mellitus were analysed for signs of MS and presence of late complications. Double diabetes was defined as T1DM coexisting with MS (obesity, hypertension, dyslipidemia). Multiple linear or logistic regression analyses were performed to identify associations between double diabetes and late complications. RESULTS: 25.5% (n=7926) of persons with T1DM presented additionally the MS. Persons with double diabetes showed significantly more macrovascular comorbidities (coronary heart disease 8.0% versus 3.0% w/o MS, stroke 3.6% versus 1.6%, diabetic foot syndrome 5.5% versus 2.1%). Also microvascular diseases were increased in people with double diabetes (retinopathy 32.4% versus 21.7%, nephropathy 28.3% versus 17.8%). Both macrovascular and microvascular comorbidities were increased independent of glucose control, even if patients with good metabolic control (HbA1c <7.0%, 53mmol/mol) showed significantly less macrovascular (coronary heart disease 2.3% versus 1.8%, p<0.0001) and microvascular problems (retinopathy 8.7% versus 6.6%, p<0.0001). CONCLUSIONS: Double diabetes seems to be an independent and important risk factor for persons with T1DM in developing macrovascular and microvascular comorbidities. Therefore, patients should be identified and development of MS should be avoided. Longterm studies are needed to observe the effect of insulin resistance on patients with autoimmune diabetes.
Authors: Adriana Lelis Carvalho; Victoria E DeMambro; Anyonya R Guntur; Phuong Le; Kenichi Nagano; Roland Baron; Francisco José Albuquerque de Paula; Katherine J Motyl Journal: J Cell Physiol Date: 2017-08-04 Impact factor: 6.384
Authors: David H Truong; Roger Bedimo; Matthew Malone; Dane K Wukich; Orhan K Oz; Amanda L Killeen; Lawrence A Lavery Journal: Open Forum Infect Dis Date: 2022-08-09 Impact factor: 4.423
Authors: Sam N Scott; Lorraine Anderson; James P Morton; Anton J M Wagenmakers; Michael C Riddell Journal: Nutrients Date: 2019-05-07 Impact factor: 5.717
Authors: Anne Helen Hansen; Meghan Bradway; Jan Broz; Tor Claudi; Øystein Henriksen; Silje C Wangberg; Eirik Årsand Journal: J Med Internet Res Date: 2019-05-29 Impact factor: 5.428